34. Neurofibromatosis Clinical trials / Disease details

Clinical trials : 137 / Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200

7 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01345136 (ClinicalTrials.gov)	July 1, 2015	21/4/2011	Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma	A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma	Neurofibromatosis Type 2;Neuroma, Acoustic	Drug: RAD001, everolimus	Jonsson Comprehensive Cancer Center	Novartis Pharmaceuticals	Active, not recruiting	16 Years	65 Years	All	4	Phase 2	United States
2	NCT02332902 (ClinicalTrials.gov)	February 2015	12/12/2014	Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T	Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1- CRAD001CUS232T	Neurofibromatosis 1	Drug: Everolimus	The University of Texas Health Science Center, Houston	Texas Neurofibromatosis Foundation	Completed	18 Years	N/A	All	24	Phase 2	United States
3	NCT01661283 (ClinicalTrials.gov)	September 2012	7/8/2012	SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors	Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors	Malignant Peripheral Nerve Sheath Tumors;MPNST;Sarcoma	Drug: everolimus;Drug: bevacizumab	Sarcoma Alliance for Research through Collaboration	Novartis Pharmaceuticals;Genentech, Inc.;United States Department of Defense	Completed	18 Years	N/A	All	25	Phase 2	United States
4	NCT01365468 (ClinicalTrials.gov)	April 2012	27/5/2011	Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)	A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1)	Plexiform Neurofibroma Associated With Neurofibromatosis Type 1	Drug: Everolimus (RAD001)	Novartis Pharmaceuticals	NULL	Terminated	6 Years	N/A	All	9	Phase 2	Israel
5	NCT01419639 (ClinicalTrials.gov)	October 2011	17/8/2011	Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2	Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2	Neurofibromatosis Type II	Drug: Everolimus (RAD001) , Afinitor®	New York University School of Medicine	Novartis Pharmaceuticals;The Children's Tumor Foundation	Completed	3 Years	N/A	All	10	Phase 2	United States
6	NCT01412892 (ClinicalTrials.gov)	April 2011	8/8/2011	Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas	A Single Arm, Multicenter Phase II a Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas That Cannot be Removed by Surgery	Neurofibromatosis Type 1;Plexiform Neurofibroma;Neurofibromatoses	Drug: RAD001: Everolimus	Assistance Publique - Hôpitaux de Paris	Novartis	Completed	18 Years	60 Years	Both	30	Phase 2	France
7	EUCTR2016-001563-36-Outside-EU/EEA (EUCTR)		12/05/2016	Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)	A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1)	Plexiform Neurofibroma Associated With Neurofibromatosis Type 1;Therapeutic area: Diseases [C] - Cancer [C04]	Trade Name: Votubia Product Name: Everolimus Product Code: RAD001	Novartis Pharmaceuticals	NULL	NA			Female: yes Male: yes	26	Phase 4	Israel